Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

158 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study.
Govers TM, Hessels D, Vlaeminck-Guillem V, Schmitz-Dräger BJ, Stief CG, Martinez-Ballesteros C, Ferro M, Borque-Fernando A, Rubio-Briones J, Sedelaar JPM, van Criekinge W, Schalken JA. Govers TM, et al. Prostate Cancer Prostatic Dis. 2019 Mar;22(1):101-109. doi: 10.1038/s41391-018-0076-3. Epub 2018 Aug 20. Prostate Cancer Prostatic Dis. 2019. PMID: 30127462
Optimizing the clinical utility of PCA3 to diagnose prostate cancer in initial prostate biopsy.
Rubio-Briones J, Borque A, Esteban LM, Casanova J, Fernandez-Serra A, Rubio L, Casanova-Salas I, Sanz G, Domínguez-Escrig J, Collado A, Gómez-Ferrer A, Iborra I, Ramírez-Backhaus M, Martínez F, Calatrava A, Lopez-Guerrero JA. Rubio-Briones J, et al. BMC Cancer. 2015 Sep 11;15:633. doi: 10.1186/s12885-015-1623-0. BMC Cancer. 2015. PMID: 26362197 Free PMC article.
A Preliminary Study of the Ability of the 4Kscore test, the Prostate Cancer Prevention Trial-Risk Calculator and the European Research Screening Prostate-Risk Calculator for Predicting High-Grade Prostate Cancer.
Borque-Fernando Á, Esteban-Escaño LM, Rubio-Briones J, Lou-Mercadé AC, García-Ruiz R, Tejero-Sánchez A, Muñoz-Rivero MV, Cabañuz-Plo T, Alfaro-Torres J, Marquina-Ibáñez IM, Hakim-Alonso S, Mejía-Urbáez E, Gil-Fabra J, Gil-Martínez P, Ávarez-Alegret R, Sanz G, Gil-Sanz MJ. Borque-Fernando Á, et al. Actas Urol Esp. 2016 Apr;40(3):155-63. doi: 10.1016/j.acuro.2015.09.006. Epub 2015 Nov 18. Actas Urol Esp. 2016. PMID: 26598800 English, Spanish.
The management of active surveillance in prostate cancer: validation of the Canary Prostate Active Surveillance Study risk calculator with the Spanish Urological Association Registry.
Borque-Fernando Á, Rubio-Briones J, Esteban LM, Collado-Serra A, Pallás-Costa Y, López-González PÁ, Huguet-Pérez J, Sanz-Vélez JI, Gil-Fabra JM, Gómez-Gómez E, Quicios-Dorado C, Fumadó L, Martínez-Breijo S, Soto-Villalba J. Borque-Fernando Á, et al. Oncotarget. 2017 Oct 24;8(65):108451-108462. doi: 10.18632/oncotarget.21984. eCollection 2017 Dec 12. Oncotarget. 2017. PMID: 29312542 Free PMC article.
Variability in the multicentre National Registry in Active Surveillance; a questionnaire for urologists.
Rubio-Briones J, Borque-Fernando A, Esteban-Escaño LM, Martínez-Breijo S, Medina-López R, Hernández V; en representación del Grupo Colaborativo PIEM-AEU Vigilancia Activa 2014 001 NCT02865330. Rubio-Briones J, et al. Actas Urol Esp (Engl Ed). 2018 Sep;42(7):442-449. doi: 10.1016/j.acuro.2018.01.007. Epub 2018 Apr 13. Actas Urol Esp (Engl Ed). 2018. PMID: 29661508 Free article. English, Spanish.
Role of the 4Kscore test as a predictor of reclassification in prostate cancer active surveillance.
Borque-Fernando Á, Rubio-Briones J, Esteban LM, Dong Y, Calatrava A, Gómez-Ferrer Á, Gómez-Gómez E, Gil Fabra JM, Rodríguez-García N, López González PÁ, García-Rodríguez J, Rodrigo-Aliaga M, Herrera-Imbroda B, Soto-Villalba J, Martínez-Breijo S, Hernández-Cañas V, Soto-Poveda AM, Sánchez-Rodríguez C, Carrillo-George C, Hernández-Martínez YE, Okrongly D. Borque-Fernando Á, et al. Prostate Cancer Prostatic Dis. 2019 Mar;22(1):84-90. doi: 10.1038/s41391-018-0074-5. Epub 2018 Aug 14. Prostate Cancer Prostatic Dis. 2019. PMID: 30108375
Validation of a 2-gene mRNA urine test for the detection of ≥GG2 prostate cancer in an opportunistic screening population.
Rubio-Briones J, Borque-Fernando A, Esteban LM, Mascarós JM, Ramírez-Backhaus M, Casanova J, Collado A, Mir C, Gómez-Ferrer A, Wong A, Aragón F, Calatrava A, López-Guerrero JA, Groskopf J, Schalken J, Van Criekinge W, Domínguez-Escrig J. Rubio-Briones J, et al. Prostate. 2020 May;80(6):500-507. doi: 10.1002/pros.23964. Epub 2020 Feb 20. Prostate. 2020. PMID: 32077525
Update and optimization of active surveillance in prostate cancer in 2021.
Rubio-Briones J, Pastor Navarro B, Esteban Escaño LM, Borque Fernando A. Rubio-Briones J, et al. Actas Urol Esp (Engl Ed). 2021 Jan-Feb;45(1):1-7. doi: 10.1016/j.acuro.2020.09.002. Epub 2020 Oct 16. Actas Urol Esp (Engl Ed). 2021. PMID: 33070989 Review. English, Spanish.
158 results